Important contributions in the management of mitral regurgitation (MR) date back several decades, 17 yet the optimal treatment strategy for IMR remains the subject of active debate, with increasing controversy regarding appropriate therapy for this patient population. 18, 19 Several studies, including a 2009 meta-analysis, have reported no survival benefit to adding MV repair to coronary artery bypass grafting (CABG) for patients with IMR 20-25 ; however, conflicting reports exist, including results from a multicenter randomized trial reported by Deja et al suggesting that MV repair may improve survival compared with CABG alone. [26] [27] [28] [29] [30] [31] [32] The utility of the current body of evidence in guiding clinical management of IMR is further limited by the preponderance of small patient samples, 21, 22, 25, 27, 30 outdated studies inadequately capturing current IMR assessment techniques and perioperative surgical risk, 20,23,26 and lack of comparison groups sufficient to capture the full range of treatment modalities, including medical management, percutaneous coronary intervention (PCI), and Background-The optimal treatment for ischemic mitral regurgitation remains actively debated. Our objective was to evaluate the relationship between ischemic mitral regurgitation treatment strategy and survival. Methods and Results-We retrospectively reviewed patients at our institution diagnosed with significant coronary artery disease and moderate or severe ischemic mitral regurgitation from 1990 to 2009, categorized by medical treatment alone, percutaneous coronary intervention, coronary artery bypass grafting (CABG), or CABG plus mitral valve repair or replacement . Kaplan-Meier methods and multivariable Cox proportional hazards analyses were performed to assess the relationship between treatment strategy and survival, with the use of propensity scores to account for nonrandom treatment assignment. A total of 4989 patients were included: medical treatment alone=36%, percutaneous coronary intervention=26%, CABG=33%, and CABG plus mitral valve repair or replacement=5%. Median follow-up was 5.37 years. Compared with medical treatment alone, significantly lower mortality was observed in patients treated with percutaneous coronary intervention (adjusted hazard ratio, 0.83; 95% confidence interval, 0.76-0.92; P=0.0002), CABG (adjusted hazard ratio, 0.56; 95% confidence interval, 0.51-0.62; P<0.0001), and CABG plus mitral valve repair or replacement (adjusted hazard ratio, 0.69; 95% confidence interval, 0.57-0.82; P<0.0001). There was no significant difference in these results based on mitral regurgitation severity. Conclusions-Patients with significant coronary artery disease and moderate or severe ischemic mitral regurgitation undergoing CABG alone demonstrated the lowest risk of death. CABG with or without mitral valve surgery was associated with lower mortality than either percutaneous coronary intervention or medical treatment alone. (Circulation. 2014;129:2547-2556.)
M ore than 600 000 patients underwent hospital admission for acute myocardial infarction in the United States in 2010, and >7.9 million Americans have a history of myocardial infarction. 1, 2 Ischemic mitral regurgitation (IMR) has been reported to occur in >50% of patients after an acute myocardial infarction, representing a distinct clinical entity from degenerative structural causes of mitral valve (MV) insufficiency. [3] [4] [5] [6] [7] [8] The presence of IMR is associated with poor outcomes, 9 and whereas outcomes are worse with increasing IMR severity, even mild IMR portends a significantly increased risk of heart failure and death. [10] [11] [12] [13] [14] [15] [16] CABG with and without MV repair or replacement. [26] [27] [28] [29] [30] Given the lack of sufficient evidence to build consensus in treating IMR, multiple investigators have called for randomized trials to better support clinical decision making. 4, 5, 11, 13, 14, 18, 25, 26 Medical management has recently been advocated as the standard of care for functional MR. 33, 34 This is in contrast to an evaluation of the Duke Cardiovascular Disease Database for patients treated from 1986 to 2001 that demonstrated that revascularization (PCI or CABG with or without MV surgery) provides a significant longevity benefit compared with medical therapy as an initial strategy. 20 Our objective in this study was to extend these observations to include advances in PCI technology and MV surgical techniques and to extend the duration of follow-up for this important manifestation of ischemic heart disease.
Methods
This study was approved by the institutional review board of Duke University Medical Center.
Data Source
The Duke Databank of Cardiovascular Disease was used for this study. This is a prospective clinical database of >200 000 patients who have undergone cardiac catheterization at Duke University Medical Center since 1969. 35 The Duke Databank of Cardiovascular Disease includes baseline variables from the patients' history, physical examination, laboratory studies, and imaging and diagnostic studies as well as the results of procedures including PCI and cardiac surgery.
Patient follow-up was conducted by the Duke Clinical Research Institute Follow-Up Services Group, which is responsible for collecting annual follow-up data on death and other clinical events for patients in the Duke Databank of Cardiovascular Disease. Annual surveys collect data on survival, hospitalizations, myocardial infarction, stroke, cardiac procedures, and medication use. Patients are surveyed 6 months after their index catheterization and yearly thereafter by means of a mailed, self-administered questionnaire. Nonresponders are surveyed by telephone. For mortality data, the response rate is 95%, and there is an annual search of the National Death Index for patients who are lost to follow-up (2%) or who have requested not to be contacted (3%). Information on death is collected through next-of-kin interviews, reviews of hospital discharge summaries and death certificates, and the National Death Index, which provides the cause of death according to the International Classification of Diseases, Tenth Revision.
Study Design
We performed a retrospective cohort analysis of all patients undergoing cardiac catheterization at our institution between January 1, 1990, and June 7, 2009, who had significant coronary artery disease (≥75% lesion in ≥1 coronary vessels) and moderate or severe (≥2+) MR on the basis of the maximum MR grade by echocardiography or left ventriculography. For patients with both echocardiographic data and ventriculography, the echocardiogram was given higher priority in determining MR grade. For a small number of patients (<3%), MR grade was determined by cardiac catheterization reports outside of our institution. Patients were excluded if there was no evidence of significant coronary artery disease, prior history of CABG, history of aortic or pulmonic valvular disease, concomitant valve disease (excluding tricuspid regurgitation), MV prolapse, congenital heart disease, myxomatous or rheumatic MV disease, or endocarditis.
Patients were analyzed according to whether they initially underwent medical management, PCI, CABG alone, or CABG plus mitral valve repair or replacement (MVRR) within 30 days of catheterization. To minimize the influence of waiting-time bias, patients who died in the medical management group within 5 days of catheterization were excluded. Operative strategies for PCI and CABG were at the discretion of the treating physician. Similarly, the decision to perform MVRR and the choice of mitral prosthesis were at the discretion of the attending surgeon. Once a patient was assigned to a treatment category, he or she was maintained in that group until death or the end of the follow-up period, regardless of therapeutic crossovers. The primary predictor variable was IMR treatment strategy, and the outcome variable was overall survival.
Statistical Analysis
Baseline characteristics were described for the overall population and by treatment strategy with the use of medians, 25th and 75th percentiles for continuous variables, and proportions for discrete variables. Comparisons for continuous and ordered categorical variables were made with the use of Kruskal-Wallis tests, and unordered categorical variables were compared with the Pearson χ 2 test. Survival curves were constructed for each group with the use of the Kaplan-Meier method, and comparisons were made with the logrank test. Cox proportional hazards models were used to evaluate the univariable association of relevant patient and disease characteristics (Table 1) with overall survival. Multivariable adjusted Cox proportional hazards modeling was used to assess the independent effect of treatment strategy on survival. Covariates included for risk adjustment in the multivariable model were determined by stepwise, linear regression with the entry criterion of P<0.10 from the http://circ.ahajournals.org/ Downloaded from univariable analysis. Additionally, to account for nonrandom treatment assignment, factors favoring selection of one treatment strategy over another were adjusted for by propensity scores. The propensity score for an individual, defined as the conditional probability of a given treatment conditionally on (or only on the basis of) the individual's covariate values, can be used to balance the covariates between groups and thus reduce bias. 36 To estimate the likelihood of each treatment modality, pairwise propensity score models between each combination of treatment pairs were created with the use of all possible clinically relevant variables. No interactions were included in the propensity score models. We created a propensity score for each treatment pair (medical treatment alone versus PCI, medical treatment alone versus CABG, medical treatment alone versus CABG+MV, PCI versus CABG, PCI versus CABG+MV, and CABG versus CABG+MV). Linearity of the propensity scores was tested, and there was no significant violation of linearity. As such, the propensity scores were then included as additional covariates in the riskadjusted Cox proportional hazards model without stratification into quintiles given the test of linearity as noted above. As verification of this approach, analysis with the use of propensity score quintiles was also performed to ensure no difference in results (data not shown). The adjusted survival curve for each group was then constructed by applying its estimated baseline hazard function, along with covariate Cox model parameter estimates, to all patients in the cohort and then averaged over all patients at each time point. The resulting curves represent a survival estimate that would have been realized had all patients been in each treatment group.
Sensitivity Analysis Based on MR Severity
A sensitivity analysis was performed to assess differences in survival end points based on the degree of MR severity. This analysis incorporated a cross-product term (or interaction term) designed to assess for a nonadditive simultaneous influence of 2 independent variables (MR severity and treatment category) on the dependent variable of overall survival. 37 The interaction term of treatment category and MR severity (dichotomized as moderate MR [2+ or 3+] and severe MR [4+]) was forced into the aforementioned Cox proportional hazards model.
A P value ≤0.05 was used to indicate statistical significance for all comparisons and analyses. All P values are 2 sided. Statistical analyses were performed with the use of SAS version 8.2 (SAS Institute Inc, Cary, NC).
Results

Study Population
A total of 109 438 cardiac catheterizations were performed at our institution within the study period. Of these, 22 571 cases were excluded because of the absence of coronary artery disease or lack of MR assessment; 49 759 were excluded because of MR grade ≤1; and 32 119 were excluded because of preexisting conditions, concomitant disease, or patients in the medical management group who died within 5 days of catheterization (n=73; Figure 1 ). This resulted in 4989 patients included in our study population, of which 1800 (36%) received medical management, 1295 (26%) underwent PCI, 1651 (33%) were treated with CABG alone, and 243 (5%) underwent CABG+MVRR. The assigned MR grade was determined by echocardiography for 68% of the study population (n=3394), with 32% (n=1595) determined by left ventriculography.
Baseline Characteristics
The median age for our study population was 67 years (25th to 75th percentiles [Q1 to Q3], 58-74), with 44.6% female and 73.1% white ethnicity. The majority of patients had 3-vessel coronary disease (43.1% of the study population) and 2+ MR (70.0% of the study population).
Patients undergoing medical management were significantly older than patients receiving other treatment modalities (median, 68 years; Q1 to Q3, 59-76) and had a higher incidence of diabetes mellitus (39.3%), chronic obstructive pulmonary disease (10.4%), peripheral vascular disease (16.3%), and cerebrovascular disease (17.6%), with a lower glomerular filtration rate (median, 63.1 mL/min per 1.73 m 2 ; Q1 to Q3, 43.5-79.5) and ejection fraction (median, 40%; Q1 to Q3, 26% to 60%) as well as higher incidence of end-stage renal disease requiring dialysis (2.7%; Table 2 ). Patients undergoing PCI had a significantly higher body mass index compared with the other groups (median, 27.3 kg/m 2 ; Q1 to Q3, 24.1-31.0), were more frequently female (51.0%), and were more likely to have 1-or 2-vessel coronary disease (51.0% and 33.6%, respectively). Patients undergoing CABG alone were more likely to be white (78.4%) and to have 3-vessel coronary disease (70.9%), hyperlipidemia (52.9%), or moderate (2+) MR (77.8%), whereas patients undergoing CABG+MVRR were more likely to have >2+ MR (93.4%) or to be classified as New York Heart Association class II to IV (54.4%). There was no significant difference in the incidence of hypertension, smoking, or family history of coronary artery disease.
Trends in Treatment Modality
During the first 10 years of the study period, more patients received medical management than the other treatment modalities, whereas in the latter 10 years of the study, CABG alone was the most common treatment strategy (Figure 2A ). The proportion of patients treated medically declined from 44.4% in the first 5 years of the study to 27.3% in the last 5 years. The proportion of patients treated with PCI rose from 25.1% to 27.3%, the proportion of patients treated with CABG rose from 26.6% to 39.0%, and the proportion of patients treated with CABG+MVRR rose from 3.9% to 6.3%. The use of pacemaker or defibrillator therapy in the medical management group steadily increased from 4.0% in the first 5 years of the study to 29.4% in the latter 5 years ( Figure 2B ).
Long-Term Survival
The median duration of follow-up for the study was 5.37 years. With the use of Kaplan-Meier methods, the median unadjusted survival was 4.4 years for patients undergoing Figure 3 ). The median adjusted survival was 5.6 years for patients undergoing medical management, 6.8 years for patients treated with PCI, 9.7 years for patients undergoing CABG alone, and 8.1 years for the CABG+MVRR group (Figure 4) . The results of the Cox proportional hazards analysis identifying the independent relationship between clinical variables and mortality are shown in Table 3 . After adjustment for other important clinical characteristics, the PCI, CABG alone, and CABG+MVRR groups all demonstrated significantly lower risk of death compared with medical therapy. Compared with patients receiving medical therapy, the CABG alone group demonstrated the lowest risk of death (adjusted hazard ratio, 0.56; 95% confidence interval, 0.51-0.62; P<0.0001), followed by CABG+MVRR (adjusted hazard ratio, 0.69; 95% confidence interval, 0.57-0.82; P<0.0001) and PCI (adjusted hazard ratio, 0.83; 95% confidence interval, 0.76-0.92; P=0.0002). There was no significant difference in these results when the propensity score was stratified by quintiles (data not shown).
Sensitivity Analysis Based on MR Severity
The cross-product interaction term of MR severity and treatment group was not statistically significant when analyzed as part of the multivariable Cox proportional hazards model (P=0.61), indicating that the adjusted risk of death based on treatment group did not differ significantly in cases of moderate versus severe MR.
Discussion
Typically, postinfarct left ventricular remodeling results in apical and inferior papillary muscle displacement and mitral annular dilatation, with the combination of these geometric changes resulting in the restriction of otherwise structurally normal mitral leaflets and thus IMR. 16, 38, 39 Because of the combined effects of ischemia and MR, these patients may have significant heart failure symptoms and can pose significant clinical management challenges. Because of the complex and dynamic nature of IMR, controversy exists in regard to the appropriate management of these patients. The present study increases the body of evidence for clinical decisions in IMR treatment by reporting the largest real-world series from the modern era including the full spectrum of treatment strategies.
This study is an extension of previous research from our institution demonstrating that IMR patients have increased longevity with revascularization by any means (with or without valve surgery in the CABG group) compared with an initial medical treatment strategy. 20 In the present analysis, we have increased the study population from 2757 to In the previously reported study, we were not able to discriminate between the revascularization methods. The present analysis confirms the superiority of revascularization to medical therapy. Additionally, these data are now able to demonstrate that CABG alone may provide optimal survival and that surgical therapy, regardless of the treatment of the MV itself, is superior to PCI. These findings are aligned with observational and randomized trials comparing CABG and PCI, suggesting that the treatment of the coronary disease dominates the effect on longevity outcome and that IMR and associated mortality are predominantly driven by ventricular pathology.
Long-Term Survival
In our investigation, treating IMR patients with revascularization (CABG alone or PCI) was associated with significantly higher long-term survival compared with medical management after adjustment for patient demographics, comorbidities, and disease characteristics. This is in contrast to current literature advocating medical management as the standard of care for functional MR. 33, 34 The inclusion of patients initially managed medically makes our data set unique in its ability to further advance the debate on this issue by demonstrating superior survival with surgical intervention, which ongoing randomized clinical trials evaluating IMR would likely be underpowered to detect. 40, 41 These findings are consistent with other studies in the literature that have proposed that revascularization alone may improve left ventricular wall motion and geometry, restoring valvular coaptation and thereby improving IMR. 20, 23 Importantly, our study demonstrates that CABG with or without MV surgery is associated with better outcomes than PCI in patients with IMR. Although some of the better survival seen by the CABG alone group can be explained by the survival advantage of CABG compared with PCI for all patients with coronary artery disease, 42 this relationship in our study was particularly pronounced. Campwala et al 43 previously reported progression of IMR in cases of incomplete coronary revascularization, which may in part explain the better survival of patients undergoing CABG compared with PCI in the present study. It is important to note that MR in our study population was determined by echocardiography or ventriculography, excluding structural or degenerative causes of MR, as has been established previously in the literature. 20, 26, 27, 44 All echocardiograms were performed at Duke, reviewed at the time of the study, and prospectively databased for MV pathology and MR etiology. These data were accessed directly for this study. Ventriculography performed outside of the Duke system (<3%) was interpreted by the treating physicians, and categorical data regarding these features were also prospectively entered into the database. Neither Duke studies nor external studies (unavailable to the authors) were independently reviewed in the preparation of this report. Detailed information in regard to the morphology of the MV to confirm leaflet tethering or wall motion abnormalities is not available in our data set; however, data from the Surgical Treatment for Ischemic Heart Failure (STICH) trial demonstrate that measurements associated with ischemic MR severity are complex and heterogeneous in nature, and therefore quantifying MR on the basis of valve morphology would also be subject to limitations. 45 Our results should therefore be analyzed in coordination with smaller prospective studies incorporating valve morphology information.
Concomitant MV Surgery
Interestingly, our analysis revealed no better survival associated with concomitant MV surgery compared with CABG alone, with no difference in these results based on MR severity or when MV replacement was excluded from the analysis (data not shown). It has been hypothesized that the correction of MR may be of little benefit because of the remaining presence of the underlying ischemic injury, implying that MR may reflect ischemia or advanced left ventricular dysfunction and therefore not have an independent impact on survival. 3, 5, 30, 46 Although several retrospective studies in which propensity score-matched cohorts of patients were used showed that CABG combined with MV repair reduced MR, these studies have not demonstrated a survival advantage. 6, 21, 47 However, an analysis of the impact of MR on survival in the STICH trial reported observational data in 91 patients with moderate to severe MR randomized to CABG with (n=49) or without (n=42) MV surgery at the discretion of the surgeon. 31 Their results demonstrated a survival advantage in adding MV surgery compared with CABG alone after adjustment for baseline variables; however, a limitation noted by the authors is the potential for surgeons to perform CABG alone in higher-risk patients as well as the relatively small sample size.
Additionally, these opposing findings from the STICH trial compared with the present study could relate to a lower ejection fraction in the STICH population (median of 25% compared with 48% in the present study). Of note, 6 of 7 perioperative deaths in their cohort occurred in patients receiving CABG alone. The authors note the need for additional observations in larger numbers of patients undergoing CABG with moderate to severe MR to confirm whether failure to repair MR in this patient population decreases long-term survival, and our results of 1651 patients undergoing CABG alone argue against this hypothesis. However, it is important to note that compared with the CABG group, the CABG+MVRR group contained a much higher proportion of patients with MR grade 4+ (52.7% versus 2.4%) and New York Heart Association class III to IV (39.3% versus 14.1%). This could indicate a higher degree of illness in patients treated with CABG+MVRR, which may not entirely be accounted for by statistical methods. Additionally, these data may indicate that MR was the inciting event leading to an intervention for the CAGB+MVRR group as opposed to cardiac ischemia, which we cannot completely discern in our data set; however, these data do not indicate that MR was the most frequent trigger for surgical intervention in the CABG group (without MV surgery) because the CABG group had a lower proportion of patients with MR grade 3+ or 4+ (22.23%) compared with both medical management (34%) and PCI (22.24%).
Additional Outcome Considerations
Even without a survival advantage, however, correction of MR may affect other important end points, such as sequelae of heart failure, 29, 30, 48 with important implications for both patient quality of life and the utilization of healthcare resources. 9 Moreover, postoperative improvement of left ventricular dysfunction by CABG alone cannot be predicted reliably, 23 and some have advocated that correction of MR may allow for significant reverse left ventricular remodeling after surgery. 32, 49, 50 The Randomized Ischemic Mitral Evaluation (RIME) trial (http:// www.clinicaltrials.gov; unique identifier NCT00413998) has provided additional support for potential benefits of MV repair in addition to CABG by demonstrating greater improvement in functional capacity, as measured by peak oxygen consumption, and greater left ventricular reverse remodeling, as measured by left ventricular end-systolic volume index, reduction in MR severity, and B-type natriuretic peptide levels, compared with CABG alone. 40 There was, however, a trend toward higher complications in patients undergoing CABG with MV repair, and current data are limited to 1-year results.
Future Contributions in IMR Management
These results further underscore the need for continued randomized trials to provide more definitive guidance in managing patients with IMR. The RIME trial has recently reported 1-year results. 40 41 This study included 301 patients with moderate IMR randomized to CABG or CABG with MV repair. An important limitation to the present study in determining the appropriateness of adding MV surgery to CABG is the absence of functional and quality of life metrics, for which the Cardiothoracic Surgical Trials Network results are anxiously awaited for additional information pertaining to these end points. Furthermore, clinical equipoise exists in the decision to repair or replace the MV in treatment of severe IMR, and, as such, the Cardiothoracic Surgical Trials Network is also conducting a trial to evaluate CABG plus mitral repair versus replacement for severe IMR and has completed enrollment of 251 patients (http://www.clinicaltrials.gov; unique identifier NCT00807040). Results from these trials will further elucidate the optimal treatment algorithm for patients with IMR; however, as with other cardiac surgery trials in the past, these may be limited by insufficient power to fully detect causal relationships with low-rate events such as mortality, 24 suggesting a continued role for large observational studies to guide clinical decisions in managing this disease process.
Limitations
The results of this investigation should be interpreted in the context of the limitations of the study. First, this was an observational study, and therefore allocation to a treatment strategy was not randomized. Modeling techniques, including propensity score adjustment, may not entirely account for the lack of randomization between cohorts. Imbalances in the baseline characteristics between treatment groups were by guest on July 26, 2017 http://circ.ahajournals.org/ Downloaded from present and may have affected our results because of selection bias and unmeasured confounders. Subjects in the medical management group were older, with higher rates of chronic obstructive pulmonary disease, peripheral vascular disease, and cerebrovascular disease, whereas the CABG group demonstrated a higher ischemic burden on the basis of the number of diseased vessels, and the CABG+MVRR group likely suffered more MV disease on the basis of MR severity and New York Heart Association class. These differences may not be entirely accounted for by statistical methods of comparison. Additionally, outcome measures other than survival were not analyzed, such as quality of life or subsequent use of resources to achieve the demonstrated survival. Furthermore, our study population excludes patients with a previous CABG. A significant portion of these patients could develop IMR and may warrant further study specific to IMR after surgical revascularization. Despite these limitations, however, our series of a 20-year longitudinal analysis represents the largest clinical study comparing the full spectrum of treatment strategies for patients with moderate to severe IMR. Although there are inherent limitations to this analysis, randomized trials with power equivalent to that of the present study would not be feasible, and level B evidence will likely remain an important component of the literature guiding decisions in treating IMR.
Conclusion
Compared with medical management, revascularization with or without treatment of the MV is associated with significantly longer survival for patients with IMR. CABG alone demonstrated the lowest risk of death, and CABG with or without MV surgery was associated with better outcomes than either PCI or medical therapy.
